# DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML

> **NCT00589082** · PHASE3 · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto**

## Conditions studied

- AML
- Elderly

## Interventions

- **DRUG:** DaunoXome
- **DRUG:** Daunorubicine

## Key facts

- **NCT ID:** NCT00589082
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** — (—)
- **Last updated:** 2008-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00589082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00589082, "DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00589082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*